表紙
市場調査レポート

高齢者ケア市場:製品・サービス

The Elder Care Market: Products and Services

発行 BCC Research 商品コード 92232
出版日 ページ情報 英文 164 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
高齢者ケア市場:製品・サービス The Elder Care Market: Products and Services
出版日: 2016年02月16日 ページ情報: 英文 164 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

米国の高齢者ケア市場は、2014年には3,816億米ドル、2015年には4,170億米ドルの規模に達し、更に今後6年間で年平均(CAGR)4.2%で成長して、2020年には5,127億米ドルにまで拡大すると見られています。

当レポートでは、米国の高齢者ケア市場について分析し、世界と米国の人口高齢化の状況や、関連法制度・政策の実情、部門別(医療、住宅・パーソナルケア、支援技術など)の市場動向(今後6年間の予測値)、主要企業のプロファイル(事業・製品概要)などをまとめた結果をお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 世界の高齢者人口の概況

  • 定義
  • 世界の高齢化の傾向
  • 世界の高齢者を巡る環境
  • 米国の高齢者
  • 米国政府の高齢者向けの法規制・プログラム
  • 米国政府および民間の栄養プログラム
  • 終末期に関する考察

第4章 分野別の産業動向:医療

  • 米国の65歳以上の高齢者向け医療
  • 関節炎
  • 心血管疾患
  • がん
  • 糖尿病
  • 感覚障害
  • 神経性疾患
  • 栄養補助食品
  • 整形外科手術
  • 呼吸器系
  • その他の慢性的な症状
  • 高齢者向け医療業界におけるM&A

第5章 分野別の産業動向:住宅

  • 無報酬の介護者
  • 長期的ケア
  • 米国の65歳以上の高齢者向け住宅
  • 市場分析
  • 自宅に居住するための改装
  • 家庭医療サービス
  • 成人用デイケアセンター
  • 低所得者向け住宅
  • 高齢者向けの施設ケアの代替策
  • アシステッドリビング・高度看護・記憶ケアのプロバイダー
  • 大手業者
  • アシステッドリビング(日常動作支援介護)
  • 高度看護施設
  • 市場の制約要因
  • 自立生活
  • 自立生活/活動的な高齢者コミュニティ
  • 高齢者住宅の市場機会
  • 米国市場の地域別分析

第6章 分野別の産業動向:アシスティブ・テクノロジー(支援技術)

  • 高齢者向けアシスティブ・テクノロジー市場の予測分析
  • 65歳以上の高齢者向けアシスティブ・テクノロジー市場の分析
  • 医療・個人モニタリング支援
  • アクセス支援
  • 日常生活支援
  • 移動支援
  • その他の支援

第7章 高齢者ケア用医薬品の開発パイプライン

  • がん
  • 糖尿病
  • 眼疾患
  • 心疾患・心臓発作
  • 腎臓病
  • 筋骨格系疾患
  • 神経疾患
  • 呼吸器系疾患

第8章 企業一覧

  • 医薬品(全20社)
  • 医療機器(全4社)
  • 住宅オプション(全9社)
  • 支援装置(全126社)

第9章 用語集

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: HLC062C

REPORT HIGHLIGHTS

The U.S. eldercare market reached $381.6 billion in 2014 and nearly $417 billion in 2015. The market should reach $512.7 billion in 2020, demonstrating a compound annual growth rate (CAGR) of 4.2% from 2015 to 2020.

This report provides:

  • An overview of the global markets for eldercare products and services.
  • Analyses of market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.
  • Segmentations of the market into healthcare products and services, housing services and needs, and assistive technologies.
  • Breakdowns of the U.S. and worldwide markets by demographics.
  • A focus on applications including:
    • Heart disease/stroke.
    • Cancer treatments.
    • Kidney disease medications.
    • Diabetes medications.
    • Arthritis prescription medications.
    • Osteoporosis medications.
    • Pain medications.
    • Neurological health medications (e.g., dementia, depression).
    • Respiratory medications and products.
  • Information covering the industry's structure.
  • Profiles of major players in the industry.

SCOPE OF REPORT

This report offers forecasts by product segment (i.e., healthcare, housing, and assistive devices and technology) from 2015 through 2020, including supporting analyses for projections.

Report segments include a demographic background of the market in the U.S. and worldwide, healthcare products and services, housing services and needs, and assistive technologies for the elder care market. International markets are discussed and information is provided on industry structure.

Profiles of leading companies involved in the elder care pharmaceutical, housing and assistive device industries are provided. Information on company placement within the designated market and strategic analyses of the companies' available and emerging products are discussed.

ANALYST'S CREDENTIALS

Peggy S. Lehr is the market research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and a MS in Communication from the University of Denver. Ms. Lehr has been involved with the medical/nursing industry for more than 25 years.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • EMPHASIS OF THE REPORT
    • HEALTHCARE
    • HOUSING
    • ASSISTIVE TECHNOLOGY
      • SUMMARY TABLE: U.S. MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED, THROUGH 2020 ($ MILLIONS)
      • SUMMARY FIGURE: U.S. MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED, 2015 AND 2020 (%)

CHAPTER 3 - OVERVIEW OF GLOBAL ELDERLY POPULATION

  • DEFINITIONS
  • TRENDS IN GLOBAL AGING
    • HEALTHCARE AND AGING
      • Volunteer Care
      • In-home Care
      • Hospice Care
  • THE GLOBAL ENVIRONMENT FOR THE ELDERLY
    • GLOBAL SOCIAL ENVIRONMENT
      • Intergenerational Living Issues in Developing Countries
      • Intergenerational Living Issues in Developed Countries
    • GLOBAL HOUSING REALITY FOR THE ELDERLY
      • Europe
      • China
    • GLOBAL ECONOMIC REALITY FOR THE ELDERLY
      • Economic Trends for Elderly Outside the U.S.
        • Europe
        • India
        • Japan
      • Economic Trends for U.S. Elderly
    • GLOBAL DEMOGRAPHIC TRENDS, BY COUNTRY
      • TABLE 1: PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES, 2014 (MILLIONS/%)
  • THE ELDERLY IN THE U.S.
    • DEMOGRAPHICS IN THE U.S.
      • TABLE 2: ESTIMATED ELDERLY POPULATIONS COMPARED WITH OVERALL POPULATIONS, WITH PERCENT OF POPULATION BY U.S. STATE, 2014 (POPULATION/%)
  • HEALTH OF THE U.S. ELDERLY
    • U.S. Health Trends
    • Discrepancies in Minority Health Status
    • Elderly Living with Chronic Health Conditions
  • SHIFTING DEMOGRAPHICS IN THE U.S.
    • Racial and Ethnic Changes
  • GOVERNMENT LEGISLATION AND PROGRAMS AIMED AT THE ELDERLY
    • AMERICANS WITH DISABILITIES ACT
      • ADA and Employee Rights
    • TELECOMMUNICATIONS ACT OF 1934
    • FAIR HOUSING ACT
    • AIR CARRIER ACCESS ACT
    • VOTING ACCESSIBILITY FOR THE ELDERLY AND HANDICAPPED ACT OF 1984
    • ARCHITECTURAL BARRIERS ACT OF 1968
    • MEDICAL DEVICE LEGISLATION
    • AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009
    • AFFORDABLE CARE ACT
  • U.S. GOVERNMENT-SPONSORED AND PRIVATELY SPONSORED NUTRITION PROGRAMS
  • END-OF-LIFE CONSIDERATIONS
    • LEGAL MATTERS
    • HOSPICE CARE
    • INTERNMENT ISSUES

CHAPTER 4 - INDUSTRY TRENDS BY SECTOR - HEALTHCARE

  • U.S. HEALTHCARE FOR INDIVIDUALS OVER 65
    • TABLE 3: U.S. MARKET FOR HEALTHCARE MEDICATIONS, PRODUCTS AND SURGICAL PROCEDURES FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS/%)
  • ARTHRITIS
    • CURRENT TREATMENTS
      • Medications
      • Rheumatoid Arthritis
        • COX2 Inhibitors
        • Disease-modifying Antirheumatic Drugs
        • Biologics
        • Corticosteroids
        • NSAIDs
      • Osteoarthritis
    • THE FUTURE BURDEN OF ARTHRITIS IN THE U.S.
      • FIGURE 1: FUTURE BURDEN OF ARTHRITIS FOR INDIVIDUALS OVER 65 IN THE U.S. BY GENDER, 2010-2030 ($ MILLIONS)
    • ARTHRITIS TREATMENT MARKET PROJECTIONS
      • TABLE 4: U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • CARDIOVASCULAR DISEASES
    • CARDIOVASCULAR DISEASE IN THE U.S.
      • Risk Factors
      • Current Treatments for Heart Disease
        • Surgical Options
        • Heart Disease Medications
          • TABLE 5: SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME AND MANUFACTURER
    • CARDIOVASCULAR TREATMENT MARKET ANALYSIS
      • TABLE 6: U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS, THROUGH 2020 ($ MILLIONS)
      • TABLE 7: U.S. MARKET FOR CARDIOVASCULAR MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • CANCER
    • TYPES OF CANCERS
    • GLOBAL RISK FACTORS
    • CANCER TREATMENT MARKET ANALYSIS
      • TABLE 8: LEADING CANCER DRUG PRODUCTS, BY MANUFACTURER AND INDICATION, 2015
    • MARKET ANALYSIS FOR U.S. CANCER DRUGS
      • TABLE 9: U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH 2020 ($ MILLIONS)
      • TABLE 10: U.S. MARKET FOR CANCER DRUGS FOR INDIVIDUALS OVER AGE 65, THROUGH 2020 ($ MILLIONS)
  • DIABETES
    • TYPE 2 DIABETES INTERNATIONALLY
      • Type 2 Diabetes in Asia
    • PREVALENCE OF TYPE 2 DIABETES IN THE U.S.
    • CURRENT TREATMENT OF DIABETES
      • Type 1 Diabetes
        • Insulin
        • Insulin Administration Devices
      • Type 2 Diabetes
        • Sulfonylureas
          • TABLE 11: SULFONYLUREAS
        • Biguanides
          • TABLE 12: BIGUANIDES
        • Alpha-Glucosidase Inhibitor
        • Glitazones
        • Prandial Glucose Regulators
        • GLP-1 Analogs/Incretin Mimetics
        • Amylin Mimetic
          • TABLE 13: ORAL HYPOGYCEMICS
  • MONITORING DEVICES FOR DIABETES
    • DIABETES THERAPY MARKET LEADERS
      • FIGURE 2: DIABETES INSULIN THERAPY MARKET LEADERS, 2014 (% OF MARKET)
      • TABLE 14: TOP DIABETES DRUGS, BY DRUG AND MANUFACTURER
    • DIABETES MARKET ANALYSIS
      • TABLE 15: U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING PRODUCTS, THROUGH 2020 ($ MILLIONS)
      • TABLE 16: U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • SENSORY IMPAIRMENTS
      • TABLE 17: U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS AND PRODUCTS FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 ($ MILLIONS)
  • SPEECH IMPAIRMENT
    • WRITING DIFFICULTY
    • VISION IMPAIRMENT
      • TABLE 18: ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS OVER 40, 2010*
      • TABLE 19: U.S. MARKET FOR PRESCRIPTION DRUGS AND SURGERY TO TREAT EYE DISEASES IN INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS)
      • Macular Degeneration
        • TABLE 20: U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
      • Cataracts
        • TABLE 21: U.S. MARKET FOR CATARACT SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
      • Glaucoma
        • Ethnic Disparities
        • Glaucoma Prescription Market
          • TABLE 22: U.S. MARKET FOR GLAUCOMA PRESCRIPTION MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
      • Eyewear
        • Market for Eyewear Products for Individuals Over 65
          • TABLE 23: U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • HEARING IMPAIRMENT
    • Causes of Hearing Loss
    • Market Analysis for Hearing Aid Products
      • TABLE 24: U.S. MARKET FOR HEARING AID PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • NEUROLOGICAL DISEASES
    • TABLE 25 U.S. MARKET FOR DEMENTIA AND DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65 BY DISEASE, THROUGH 2020 ($ MILLIONS)
  • ALZHEIMER'S DISEASE
    • FIGURE 3: CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%)
    • Economic Burden
    • Current Treatments for Alzheimer's
      • TABLE 26: COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE, 2015
    • Market Analysis for Dementia Costs
      • TABLE 27: U.S. MARKET FOR DEMENTIA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • DEPRESSION
    • Origins of the Disease
    • Genetic Factors
    • Biological Factors
    • Sociological Factors
    • Psychological Factors
    • Costs of Depression
    • Market Analysis for Depression in the Elderly
      • TABLE 28: U.S. MARKET FOR DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • LIQUID NUTRITIONAL SUPPLEMENTS
    • TABLE 29 U.S. MARKET FOR LIQUID NUTRITIONAL SUPPLEMENTS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • ORTHOPEDIC
    • TABLE 30: U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND SURGERIES FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS)
  • OSTEOPOROSIS
    • TABLE 31: UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR OSTEOPOROSIS
    • Osteoporosis Medications
      • TABLE 32: OSTEOPOROSIS MEDICATIONS BY TYPE
    • Market Analysis for Osteoporosis Medications
      • TABLE 33: U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • FALLS AND THE ELDERLY
  • JOINT REPLACEMENT
    • Market Analysis
      • TABLE 34: U.S. MARKET FOR SELECTED ORTHOPEDIC SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • RESPIRATORY
    • TABLE 35: U.S. MARKET FOR RESPIRATORY MEDICATIONS AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • ALLERGIES
    • Current Treatments for Allergies
      • TABLE 36: CURRENT ALLERGY TREATMENTS
    • Allergy Market Analysis
      • TABLE 37: U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 ($ MILLIONS)
  • ASTHMA
    • Treatments
      • TABLE 38: U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • COPD
    • TABLE 39: U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • COPD Treatment Options
      • TABLE 40: CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S.
    • Emphysema
    • Chronic Bronchitis
  • OXYGEN THERAPY
    • TABLE 41: U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • LOSS OF PATENT PROTECTION
    • TABLE 42 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN 2014-2021
  • OTHER CHRONIC CONDITIONS
    • DENTAL HEALTH
    • OBESITY
    • PAIN MANAGEMENT
    • UROLOGICAL PROBLEMS
      • TABLE 43: U.S. MARKET FOR UROLOGICAL PRODUCTS FOR INDIVIDUALS OVER
  • BY CONDITION, THROUGH 2020 ($ MILLIONS)
    • Incontinence Medications
      • TABLE 44: U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • Benign Prostatic Hyperplasia (BPH)
      • TABLE 45: SELECTED MEDICATIONS FOR BPH
      • TABLE 46: U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • ACQUISITIONS AND MERGERS IN THE ELDER CARE PHARMACEUTICAL INDUSTRY
    • TABLE 47: SELECTED ACQUISITIONS AND MERGERS IN THE ELDER CARE PHARMACEUTICAL MARKET, 2013 TO 2015 ($ MILLIONS)

CHAPTER 5 - INDUSTRY TRENDS BY SECTOR - HOUSING

  • UNPAID CAREGIVERS
    • TOLL ON CAREGIVERS
  • LONG-TERM CARE
    • TABLE 48: LONG-TERM INSURANCE CARRIERS, 2015
  • LONG-TERM CARE NEEDS
    • FIGURE 4: PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER 65 (%)
  • U.S. HOUSING FOR INDIVIDUALS OVER 65
    • MARKET ANALYSIS
      • TABLE 49: U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • AT-HOME REMODELING
      • TABLE 50: U.S. MARKET FOR AT-HOME REMODELING FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • HOME HEALTHCARE SERVICES
      • TABLE 51: U.S. MARKET FOR HOME HEALTH SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • ADULT DAY CENTERS
      • TABLE 52: U.S. MARKET FOR ADULT DAY CARE SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • COMPETITIVE LANDSCAPE FOR HOME HEALTHCARE SERVICES
      • FIGURE 5: TOP HOME HEALTHCARE PROVIDERS, BY COMPANY AND PERCENT OF MARKET (%)
  • HOUSING FOR LOWER INCOME INDIVIDUALS
  • INSTITUTIONAL CARE ALTERNATIVES FOR SENIORS
  • ASSISTED LIVING, SKILLED NURSING, MEMORY CARE PROVIDERS
    • TABLE 53: U.S. MARKET FOR ASSISTED LIVING AND SKILLED NURSING FACILITIES FOR INDIVIDUALS OVER 65 BY SERVICE, THROUGH 2020 ($ MILLIONS)
  • TOP INDUSTRY PROVIDERS
    • TABLE 54: TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2014
    • TABLE 55: TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2014
    • FIGURE 6: PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN THE U.S., 2014 (%)
    • TABLE 56: TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2015
  • ASSISTED LIVING
    • OCCUPANCY RATES
  • SKILLED NURSING HOMES
    • MEMORY CARE
  • MARKET CONSTRAINTS
    • RESTRICTED SUPPLY OF NURSING BEDS
    • COST CONTAINMENT EFFORTS BY GOVERNMENT PAYERS
    • IMPLICATIONS OF THE AFFORDABLE CARE ACT (ACA)
      • Care Coordination
    • REIMBURSEMENT ISSUES
      • Medicaid Reimbursement
    • LACK OF FINANCIAL RESOURCES BY SENIORS
    • INDUSTRY COMPETITION
      • TABLE 57: SELECTED ACQUISITIONS AND MERGERS IN THE SENIOR HOUSING MARKET, 2013-2015 ($ MILLIONS)
    • RETAINING COMPETENT STAFF
  • INDEPENDENT LIVING
  • INDEPENDENT LIVING/ACTIVE ADULT COMMUNITIES
    • RECREATIONALLY BASED RETIREMENT COMMUNITIES
      • TABLE 58: U.S. MARKET FOR INDEPENDENT LIVING HOUSING FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
  • SENIOR HOUSING MARKET OPPORTUNITIES
    • MEMORY CARE FACILITIES
    • AGING IN PLACE

CHAPTER 6 - INDUSTRY TRENDS, BY SECTOR - ASSISTIVE TECHNOLOGIES

  • PROJECTED ASSISTIVE TECHNOLOGIES MARKET
    • TABLE 59: U.S. ASSISTIVE TECHNOLOGY MARKET BY TYPE, THROUGH 2020 ($ MILLIONS)
  • ASSISTIVE TECHNOLOGIES MARKET ANALYSIS FOR INDIVIDUALS OVER 65
    • TABLE 60: U.S. MARKET FOR ASSISTIVE TECHNOLOGIES FOR INDIVIDUALS OVER
  • BY TYPE, THROUGH 2020 ($ MILLIONS)
    • FIGURE 7: U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS OVER 65, 2015 AND 2020 (%)
  • MEDICAL AND PERSONAL MONITORING AIDS
    • ACTIVITY LOCATION/PERSONAL MONITORING AIDS
      • Activity/Emergency Location Monitors
      • Remote Medical Monitors
      • Market Fragmentation
    • MEDICAL/PERSONAL MONITORING AIDS MARKET GROWTH
      • TABLE 61: U.S. MARKET FOR MEDICAL/PERSONAL MONITORING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • MARKET DRIVERS FOR MEDICAL AND PERSONAL MONITORING AIDS
  • ACCESS AIDS
    • HOME ELEVATORS
    • WHEELCHAIR LIFTS
    • STAIR CLIMBERS
    • ACCESSIBLE BATHS AND SHOWERS
    • TRANSFER LIFTS
    • DOOR OPENERS
    • ACCESS AIDS MANUFACTURERS
      • TABLE 62: ACCESS AIDS MANUFACTURERS
      • TABLE 63: U.S. MARKET FOR ACCESS AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • DAILY LIVING AIDS
      • TABLE 64: SELECTED MANUFACTURERS OF DAILY LIVING AIDS
    • PROJECTED MARKET FOR DAILY LIVING AIDS FOR INDIVIDUALS OVER 65
      • TABLE 65: U.S. MARKET FOR DAILY LIVING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • MOBILITY AIDS
      • TABLE 66: U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS OVER 65 BY PRODUCT, THROUGH 2020 ($ MILLIONS)
    • WHEELCHAIRS, SCOOTERS AND ACCESSORIES
      • Wheelchairs
        • TABLE 67: WHEELCHAIR MANUFACTURERS
      • Scooters
        • TABLE 68: SCOOTER MANUFACTURERS
    • AMBULATORY AIDS
      • TABLE 69: U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
      • TABLE 70: AMBULATORY AID MANUFACTURERS
    • MOTOR VEHICLE MODIFICATIONS
      • TABLE 71: U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
      • TABLE 72: VEHICLE ASSESS CONVERSION KIT MANUFACTURERS
    • NAVIGATION AIDS
      • TABLE 73: U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
    • OTHER AIDS
      • TABLE 74: U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65 BY TYPE OF AID, THROUGH 2020 ($ MILLIONS)
    • BEDS
    • ERGONOMIC AIDS
    • COMMUNICATION AIDS
      • TABLE 75: U.S. MARKET FOR COMMUNICATION AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS)
      • Speech Aids
      • Writing Aids/Computer Access
        • Input Devices
        • Output Devices
        • Software Products
        • Telephony Accessories
        • Text Telephones
        • Amplified Telephones
      • Vision/Reading Aids

CHAPTER 7 - DEVELOPMENTAL PIPELINE FOR ELDER CARE PHARMACEUTICALS

  • TABLE 76: MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS, 2014
  • CANCER
    • BREAST
      • TABLE 77: MAJOR PRODUCT PIPELINES FOR BREAST CANCER
    • COLORECTAL CANCER
      • TABLE 78: MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER
    • BLADDER
      • TABLE 79: MAJOR PRODUCT PIPELINES FOR BLADDER CANCER
    • PROSTATE
      • TABLE 80: MAJOR PRODUCT PIPELINES FOR PROSTATE CANCER
    • SKIN
      • TABLE 81: MAJOR PRODUCT PIPELINES FOR SKIN CANCER
    • DIABETES
      • TABLE 82: MAJOR PRODUCT PIPELINES FOR DIABETES
    • EYE DISEASES
      • TABLE 83: MAJOR PRODUCT PIPELINE FOR EYE DISEASES
    • HEART DISEASE/STROKE
      • TABLE 84: MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE
    • KIDNEY DISEASE
      • TABLE 85: MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE
  • MUSCULOSKELETAL
    • OSTEOPOROSIS
      • TABLE 86: MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS
      • Rheumatoid Arthritis
        • TABLE 87: MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS
  • NEUROLOGICAL
    • DEPRESSION PRODUCT PIPELINE
      • TABLE 88: MAJOR PRODUCT PIPELINES FOR DEPRESSION
    • DEMENTIA PRODUCT PIPELINE
      • TABLE 89: MAJOR PRODUCT PIPELINE FOR DEMENTIA PHARMACEUTICALS
  • RESPIRATORY
    • ASTHMA
      • TABLE 90: MAJOR PRODUCT PIPELINES FOR ASTHMA
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
      • TABLE 91: MAJOR PRODUCT PIPELINES FOR COPD

CHAPTER 8 - COMPANY DIRECTORY

  • HEALTHCARE
    • ABBOTT LABORATORIES
      • Business Overview
      • Products
    • ALLERGAN (FORMERLY ACTAVIS)
      • Business Overview
      • Products
    • ASTRAZENECA PLC
      • Business Overview
      • Products
    • BRISTOL-MYERS SQUIBB
      • Business Overview
      • Products
    • CENTOCOR (SEE JANSSEN PHARMACEUTICALS)
    • COVIDIEN (SEE MEDTRONIC)
    • ELI LILLY
      • Business Overview
      • Products
    • ENDO PHARMACEUTICALS INC.
      • Business Overview
      • Products
    • FOREST PHARMACEUTICALS (SEE ACTAVIS)
    • GLAXOSMITHKLINE PLC
      • Business Overview
      • Products
    • JANSSEN PHARMACEUTICALS INC.
      • Business Overview
      • Products
    • JOHNSON & JOHNSON
      • Business Overview
      • Products
    • MERCK
      • Business Overview
      • Products
    • NOVARTIS INTERNATIONAL AG/SANDOZ
      • Business Overview
      • Products
    • NOVO NORDISK
      • Business Overview
      • Products
    • PFIZER
      • Business Overview
      • Products
    • PURDUE PHARMACEUTICALS LP
      • Business Overview
      • Products
    • ROCHE PHARMACEUTICALS
      • Business Overview
      • Products
    • SANOFI-AVENTIS
      • Business Overview
      • Products
    • TAKEDA PHARMACEUTICALS
      • Business Overview
      • Products
    • MEDICAL DEVICES
    • BOSTON SCIENTIFIC
      • Business Overview
      • Products
    • DJO GLOBAL INC.
      • Business Overview
      • Products
    • MEDTRONIC INC.
      • Business Overview
      • Products
    • ST. JUDE MEDICAL INC.
      • Business Overview
      • Products
    • HOUSING OPTIONS
    • BROOKDALE SENIOR LIVING
      • Business Overview
      • Products
    • CAPITAL SENIOR LIVING CORP.
      • Business Overview
      • Products
    • ENLIVANT (FORMERLY ASSISTED LIVING CONCEPTS LLC)
      • Business Overview
      • Products
    • EMERITUS CORP. (SEE BROOKDALE)
    • FIVE STAR QUALITY CARE INC.
      • Business Overview
      • Products
    • HCR MANORCARE INC.
      • Business Overview
      • Products
    • LIFE CARE CENTERS OF AMERICA
      • Business Overview
      • Products
    • LIVHOME INC.
      • Business Overview
      • Products
    • SUNRISE SENIOR LIVING INC.
      • Business Overview
      • Products
    • ASSISTIVE DEVICES
    • A&D MEDICAL/LIFESOURCE
      • Business Overview
      • Products
    • ALIMED INC.
      • Business Overview
      • Products
    • ALLIED HEALTHCARE PRODUCTS INC.
      • Business Overview
      • Products
    • AMERICAN MEDICAL ALERT CORP. (SEE TUNSTALL HEALTHCARE)
    • BAXTER INTERNATIONAL INC.
      • Business Overview
      • Products
    • BAYER AG (MILES-BAYER)
      • Business Overview
      • Products
    • BLUE CHIP MEDICAL PRODUCTS
      • Business Overview
      • Products
    • BRUNO INDEPENDENT LIVING AIDS INC.
      • Business Overview
      • Products
    • CARD GUARD AG
      • Business Overview
      • Products
    • COBOLT SYSTEMS LTD.
      • Business Overview
      • Products
    • DOLPHIN COMPUTER ACCESS LTD.
      • Business Overview
      • Products
    • DUXBURY SYSTEMS INC.
      • Business Overview
      • Products
    • ECHO THERAPEUTICS
      • Business Overview
      • Products
    • EXACT DYNAMICS B.V.
      • Business Overview
      • Products
    • FREEDOM SCIENTIFIC INC.
      • Business Overview
      • Products
    • FRESENIUS MEDICAL CARE AG & CO. KGAA
      • Business Overview
      • Products
    • GRAHAM-FIELD HEALTH PRODUCTS
      • Business Overview
      • Products
    • GW MICRO INC.
      • Business Overview
      • Products
    • HONEYWELL HOMMED
      • Business Overview
      • Products
    • HUMANWARE
      • Business Overview
      • Products
    • INCLINATOR COMPANY OF AMERICA
      • Business Overview
      • Products
    • INVACARE CORP.
      • Business Overview
      • Products
    • JOHNSON & JOHNSON
      • Business Overview
      • Products
    • KIMBERLY CLARK
      • Business Overview
      • Products
    • KROWN MANUFACTURING
      • Business Overview
      • Products
    • LIFE ALERT EMERGENCY RESPONSE
      • Business Overview
      • Products
    • LIFE GUARDIAN LLC
      • Business Overview
      • Products
    • LIFESCAN INC.
      • Business Overview
      • Products
    • LIFTAVATOR INC.
      • Business Overview
      • Products
    • MEDLINE INDUSTRIES INC.
      • Business Overview
      • Products
    • MEDTRONIC MINIMED
      • Business Overview
      • Products
    • NIPRO DIAGNOSTICS INC.
      • Business Overview
      • Products
    • NXSTAGE MEDICAL INC.
      • Business Overview
      • Products
    • OBS MEDICAL
      • Business Overview
      • Products
    • OMRON HEALTHCARE INC.
      • Business Overview
      • Products
    • OPTELEC (SEE FREEDOM SCIENTIFIC INC.)
    • OTTO BOCK HEALTHCARE LP
      • Business Overview
      • Products
    • PHILIPS LIFELINE SYSTEMS INC.
      • Business Overview
      • Products
    • PRIDE MOBILITY PRODUCTS CORP.
      • Business Overview
      • Products
    • PULSE METRIC INC.
      • Business Overview
      • Products
    • RESMED INC.
      • Business Overview
      • Products
    • ROCHE DIAGNOSTICS
      • Business Overview
      • Products
    • SAVARIA CORP.
      • Business Overview
      • Products
    • SCOTTCARE CARDIOVASCULAR SOLUTIONS
      • Business Overview
      • Products
    • SIEMENS HEARING INSTRUMENTS INC.
      • Business Overview
      • Products
    • STARKEY HEARING TECHNOLOGIES
      • Business Overview
      • Products
    • SUNRISE MEDICAL INC.
      • Business Overview
      • Products
    • SVENSKA CELLULOSA AKTIEBOLAGET SCA
      • Business Overview
      • Products
    • THORNDIKE PRESS
      • Business Overview
      • Products
    • THYSSENKRUPP NORTH AMERICA
      • Business Overview
      • Products
    • TUNSTALL AMERICAS
      • Business Overview
      • Products
    • TYCO INTERNATIONAL
      • Business Overview
      • Products
    • WIDEX A/S
      • Business Overview
      • Products

CHAPTER 9 - GLOSSARY

  • ACTIVITIES OF DAILY LIVING (ADLS)
  • ALZHEIMER'S DISEASE
  • ARTHRITIS
  • ASSISTED LIVING
  • ASSISTIVE TECHNOLOGY
  • BABY BOOMER
  • CARDIOVASCULAR DISEASE
  • CAREGIVERS
  • CONGESTIVE OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • DEMENTIA
  • DIABETES
  • DURABLE MEDICAL EQUIPMENT
  • ELDER/SENIOR
  • GERONTOLOGY
  • HOSPICE CARE
  • INSTRUMENTAL ACTIVITIES OF DAILY LIVING (IADLS)
  • LONG-TERM CARE
  • PROSTHETICS AND ORTHOTICS

LIST OF TABLES

  • SUMMARY TABLE U.S.: MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED, THROUGH 2020 ($ MILLIONS) 8
    • TABLE 1: PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES, 2014 (MILLIONS/%) 16
    • TABLE 2: ESTIMATED ELDERLY POPULATIONS COMPARED WITH OVERALL POPULATIONS, WITH PERCENT OF POPULATION BY U.S. STATE, 2014 (POPULATION/%) 17
    • TABLE 3: U.S. MARKET FOR HEALTHCARE MEDICATIONS, PRODUCTS AND SURGICAL PROCEDURES FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS/%) 27
    • TABLE 4: U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 31
    • TABLE 5: SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME AND MANUFACTURER 33
    • TABLE 6: U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS, THROUGH 2020 ($ MILLIONS) 36
    • TABLE 7: U.S. MARKET FOR CARDIOVASCULAR MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 36
    • TABLE 8: LEADING CANCER DRUG PRODUCTS, BY MANUFACTURER AND INDICATION, 2015 38
    • TABLE 9: U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH 2020 ($ MILLIONS) 40
    • TABLE 10: U.S. MARKET FOR CANCER DRUGS FOR INDIVIDUALS OVER AGE 65, THROUGH 2020 ($ MILLIONS) 41
    • TABLE 11: SULFONYLUREAS 44
    • TABLE 12: BIGUANIDES 44
    • TABLE 13: ORAL HYPOGYCEMICS 46
    • TABLE 14: TOP DIABETES DRUGS, BY DRUG AND MANUFACTURER 48
    • TABLE 15: U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING PRODUCTS, THROUGH 2020 ($ MILLIONS) 49
    • TABLE 16: U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 49
    • TABLE 17: U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS AND PRODUCTS FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 ($ MILLIONS) 50
    • TABLE 18: ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS OVER 40, 2010* 50
    • TABLE 19: U.S. MARKET FOR PRESCRIPTION DRUGS AND SURGERY TO TREAT EYE DISEASES IN INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS) 51
    • TABLE 20: U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 52
    • TABLE 21: U.S. MARKET FOR CATARACT SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 53
    • TABLE 22: U.S. MARKET FOR GLAUCOMA PRESCRIPTION MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 54
    • TABLE 23: U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 55
    • TABLE 24: U.S. MARKET FOR HEARING AID PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 56
    • TABLE 25: U.S. MARKET FOR DEMENTIA AND DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65 BY DISEASE, THROUGH 2020 ($ MILLIONS) 57
    • TABLE 26: COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE, 2015 59
    • TABLE 27: U.S. MARKET FOR DEMENTIA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 60
    • TABLE 28: U.S. MARKET FOR DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 62
    • TABLE 29: U.S. MARKET FOR LIQUID NUTRITIONAL SUPPLEMENTS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 63
    • TABLE 30: U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND SURGERIES FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS) 64
    • TABLE 31: UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR OSTEOPOROSIS 64
    • TABLE 32: OSTEOPOROSIS MEDICATIONS BY TYPE 65
    • TABLE 33: U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 66
    • TABLE 34: U.S. MARKET FOR SELECTED ORTHOPEDIC SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 67
    • TABLE 35: U.S. MARKET FOR RESPIRATORY MEDICATIONS AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 67
    • TABLE 36: CURRENT ALLERGY TREATMENTS 68
    • TABLE 37: U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 ($ MILLIONS) 70
    • TABLE 38: U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 72
    • TABLE 39: U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 73
    • TABLE 40: CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S. 73
    • TABLE 41: U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 75
    • TABLE 42: MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN 2014-2021 76
    • TABLE 43: U.S. MARKET FOR UROLOGICAL PRODUCTS FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS) 77
    • TABLE 44: U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 78
    • TABLE 45: SELECTED MEDICATIONS FOR BPH 79
    • TABLE 46: U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 79
    • TABLE 47: SELECTED ACQUISITIONS AND MERGERS IN THE ELDER CARE PHARMACEUTICAL MARKET, 2013 TO 2015 ($ MILLIONS) 80
    • TABLE 48: LONG-TERM INSURANCE CARRIERS, 2015 83
    • TABLE 49: U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 85
    • TABLE 50: U.S. MARKET FOR AT-HOME REMODELING FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 86
    • TABLE 51: U.S. MARKET FOR HOME HEALTH SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 87
    • TABLE 52: U.S. MARKET FOR ADULT DAY CARE SERVICES FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 88
    • TABLE 53: U.S. MARKET FOR ASSISTED LIVING AND SKILLED NURSING FACILITIES FOR INDIVIDUALS OVER 65 BY SERVICE, THROUGH 2020 ($ MILLIONS) 90
    • TABLE 54: TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2014 91
    • TABLE 55: TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2014 91
    • TABLE 56: TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2015 93
    • TABLE 57: SELECTED ACQUISITIONS AND MERGERS IN THE SENIOR HOUSING MARKET, 2013-2015 ($ MILLIONS) 97
    • TABLE 58: U.S. MARKET FOR INDEPENDENT LIVING HOUSING FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 99
    • TABLE 59: U.S. ASSISTIVE TECHNOLOGY MARKET BY TYPE, THROUGH 2020 ($ MILLIONS) 102
    • TABLE 60: U.S. MARKET FOR ASSISTIVE TECHNOLOGIES FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 ($ MILLIONS) 102
    • TABLE 61: U.S. MARKET FOR MEDICAL/PERSONAL MONITORING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 105
    • TABLE 62: ACCESS AIDS MANUFACTURERS 106
    • TABLE 63: U.S. MARKET FOR ACCESS AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 107
    • TABLE 64: SELECTED MANUFACTURERS OF DAILY LIVING AIDS 108
    • TABLE 65: U.S. MARKET FOR DAILY LIVING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 108
    • TABLE 66: U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS OVER 65 BY PRODUCT, THROUGH 2020 ($ MILLIONS) 109
    • TABLE 67: WHEELCHAIR MANUFACTURERS 110
    • TABLE 68: SCOOTER MANUFACTURERS 111
    • TABLE 69: U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 111
    • TABLE 70: AMBULATORY AID MANUFACTURERS 112
    • TABLE 71: U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 113
    • TABLE 72: VEHICLE ASSESS CONVERSION KIT MANUFACTURERS 113
    • TABLE 73: U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 113
    • TABLE 74: U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65 BY TYPE OF AID, THROUGH 2020 ($ MILLIONS) 114
    • TABLE 75: U.S. MARKET FOR COMMUNICATION AIDS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 115
    • TABLE 76: MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS, 2014 119
    • TABLE 77: MAJOR PRODUCT PIPELINES FOR BREAST CANCER 120
    • TABLE 78: MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER 121
    • TABLE 79: MAJOR PRODUCT PIPELINES FOR BLADDER CANCER 121
    • TABLE 80: MAJOR PRODUCT PIPELINES FOR PROSTATE CANCER 122
    • TABLE 81: MAJOR PRODUCT PIPELINES FOR SKIN CANCER 122
    • TABLE 82: MAJOR PRODUCT PIPELINES FOR DIABETES 123
    • TABLE 83: MAJOR PRODUCT PIPELINE FOR EYE DISEASES 124
    • TABLE 84: MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE 125
    • TABLE 85: MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE 126
    • TABLE 86: MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS 127
    • TABLE 87: MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS 127
    • TABLE 88: MAJOR PRODUCT PIPELINES FOR DEPRESSION 128
    • TABLE 89: MAJOR PRODUCT PIPELINE FOR DEMENTIA PHARMACEUTICALS 129
    • TABLE 90: MAJOR PRODUCT PIPELINES FOR ASTHMA 129
    • TABLE 91: MAJOR PRODUCT PIPELINES FOR COPD 130

LIST OF FIGURES

  • SUMMARY FIGURE U.S.: MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED, 2015 AND 2020 (%) 9
    • FIGURE 1: FUTURE BURDEN OF ARTHRITIS FOR INDIVIDUALS OVER 65 IN THE U.S. BY GENDER, 2010-2030 ($ MILLIONS) 30
    • FIGURE 2: DIABETES INSULIN THERAPY MARKET LEADERS, 2014 (% OF MARKET) 47
    • FIGURE 3: CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%) 58
    • FIGURE 4: PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER 65 (%) 83
    • FIGURE 5: TOP HOME HEALTHCARE PROVIDERS, BY COMPANY AND PERCENT OF MARKET (%) 88
    • FIGURE 6: PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN THE U.S., 2014 (%) 91
    • FIGURE 7: U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS OVER 65, 2015 AND 2020 (%) 103
Back to Top